Stingray Therapeutics
CEO: Jonathan Northrup
Stingray Therapeutics is a pre-clinical company developing a next-generation, cutting-edge cancer treatment technology in immune oncology.
Stingray’s technology builds on earlier generations of immune oncology drugs. Its innate immune technology is designed to stimulate immunity to fight the cancer resistance, and attack a broader range of cancers than the drugs available currently.
Stingray is investigating the potential efficacy of their technology in Medulloblastoma, a deadly pediatric brain cancer that is particularly resistant to available treatments.